Market Overview

GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

Share:
  • Issued patent expands global patent portfolio for GlycoMimetics'
    late-stage drug candidate targeting treatment of broad spectrum of
    patients with acute myeloid leukemia (AML)

GlycoMimetics, Inc. (NASDAQ:GLYC), a biopharmaceutical company focused
on discovering and developing novel small-molecule drug candidates to
treat rare diseases, announced today that the Japan Patent Office (JPO)
has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly
issued patent covers uproleselan's composition of matter as well as
pharmaceutical formulations, and expires in December 2032.

"The JPO's issuance of a patent for uproleselan extends major market
intellectual property coverage for this E-selectin antagonist drug
candidate," stated Rachel King, GlycoMimetics' Chief Executive Officer.
"As the need for novel AML treatments continues to grow worldwide, the
Japanese patent represents an important component of our intellectual
property portfolio. It protects the composition of matter of this
innovative approach to treating blood cancer."

As previously announced, the United States Patent and Trademark Office
(USPTO) and European Patent Office have issued patents directed to the
composition of matter of uproleselan, pharmaceutical formulations of
uproleselan, and methods of treating acute myelogenous leukemia. These
patents will also expire in late-2032. In addition to the above
coverage. GlycoMimetics has ongoing efforts to secure additional patents
on uproleselan and its uses to potentially extend exclusivity beyond
2032.

About Uproleselan (GMI-1271)

Uproleselan is designed to block E-selectin (an adhesion molecule on
cells in the bone marrow) from binding with blood cancer cells as a
targeted approach to disrupting well-established mechanisms of leukemic
cell resistance within the bone marrow microenvironment. In a Phase 1/2
clinical trial, uproleselan was evaluated in both newly diagnosed
elderly and relapsed/refractory patients with AML. In both populations,
patients treated with uproleselan together with standard chemotherapy
achieved better than expected remission rates and overall survival
compared to historical controls, which have been derived from results
from third party clinical trials evaluating standard chemotherapy, as
well as lower than expected induction-related mortality rates. Treatment
in these patient populations was generally well tolerated, with fewer
than expected adverse effects. The FDA has granted uproleselan
Breakthrough Therapy designation for the treatment of adult AML patients
with relapsed/refractory (R/R) disease. GlycoMimetics plans to implement
a comprehensive development program across the clinical spectrum of AML.
This will include a company sponsored Phase 3 trial in R/R AML and two
consortia-sponsored trials in newly diagnosed patients. One consortium
trial will be sponsored by the NCI and will enroll newly diagnosed
patients fit for intensive chemotherapy. The other trial will be
sponsored by the HOVON group in Europe and will enroll newly diagnosed
patients unfit for intensive chemotherapy.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics has three clinical-stage programs:
rivipansel, uproleselan and GMI-1359. In addition, the company is
researching additional pre-clinical stage compounds based on its
specialized chemistry expertise. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the
clinical development of the company's drug candidates, including the
expected timing of completion of clinical trials and the presentation of
clinical data. Actual results may differ materially from those in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the company's
annual report on Form 10-K filed with the U.S. Securities and Exchange
Commission (SEC) on March 6, 2018, and other filings GlycoMimetics makes
with the SEC from time to time. Forward-looking statements speak only as
of the date of this release, and GlycoMimetics undertakes no obligation
to update or revise these statements, except as may be required by law.

View Comments and Join the Discussion!